Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tofacitinib Citrate

FDA-approved product (tablet, oral), marketed as Tofacitinib Citrate, Xeljanz, Xeljanz Xr.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tofacitinib Citrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psoriatic arthritis
  • Rheumatoid arthritis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Janus-associated kinase (jak) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tofacitinib Citrate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tofacitinib Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications

    NCT00856544 · start 2009-05

    Registered record
    Registry ID
    NCT00856544
    Conditions
    Arthritis, Rheumatoid
    Interventions
    CP-690,550; CP-690,550; Placebo; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-05
    Completion
    2011-01
    Enrolment
    795

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArthritis, Rheumatoid
    InterventionCP-690,550; CP-690,550; Placebo; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

    NCT00784719 · start 2008-11

    Registered record
    Registry ID
    NCT00784719
    Conditions
    Dry Eye Syndromes
    Interventions
    CP-690,550; CP-690,550; CP-690,550; CP-690,550; Cyclosporine; CP-690,550 Vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2008-11
    Completion
    2009-10
    Enrolment
    327

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Syndromes
    InterventionCP-690,550; CP-690,550; CP-690,550; CP-690,550 +2 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • PsoBest - The German Psoriasis Registry

    NCT01848028 · start 2008-01

    Registered record
    Registry ID
    NCT01848028
    Conditions
    Psoriasis; Psoriatic-arthritis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2008-01
    Completion
    2032-12
    Enrolment
    3,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis; Psoriatic-arthritis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Co-Administration Of Methotrexate And CP-690,550

    NCT01745055 · start 2005-04

    Registered record
    Registry ID
    NCT01745055
    Conditions
    Rheumatoid Arthritis
    Interventions
    CP-690,550 (tofacitinib); Methotrexate (MTX)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-04
    Completion
    2006-06
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionCP-690,550 (tofacitinib); Methotrexate (MTX)
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease

    NCT01710020 · start 2003-02

    Registered record
    Registry ID
    NCT01710020
    Conditions
    End-Stage Renal Disease; Hemodialysis
    Interventions
    CP-690,550
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-02
    Completion
    2003-06
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd-Stage Renal Disease; Hemodialysis
    InterventionCP-690,550
    PhasePhase 1
    Registry statusCompleted